ATNFW
Income statement / Annual
Last year (2023), CannBioRx Life Sciences Corp.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, CannBioRx Life Sciences Corp.'s net income was -$19.94 M.
See CannBioRx Life Sciences Corp.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$105,675.00 |
$109,004.00 |
$116,297.00 |
$125,333.00 |
$72,244.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$105,675.00 |
-$109,004.00 |
-$116,297.00 |
-$125,333.00 |
-$72,244.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$2.78 M
|
$2.43 M
|
$3.95 M
|
$2.29 M
|
$2.04 M
|
$1.07 M
|
$0.00
|
| General & Administrative
Expenses |
$10.69 M
|
$15.47 M
|
$11.69 M
|
$3.32 M
|
$5.89 M
|
$7.67 M
|
$343,884.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$38,831.00
|
$12.96 M
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$10.69 M
|
$15.47 M
|
$11.69 M
|
$3.36 M
|
$18.85 M
|
$7.67 M
|
$343,884.00
|
| Other Expenses |
$0.00 |
$246.34 B |
$770,602.00 |
$264,739.00 |
$250,396.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$13.48 M |
$39.64 M |
$20.16 M |
$9.82 M |
$25.22 M |
$14.51 M |
$343,884.00 |
| Cost And Expenses |
$13.48 M |
$39.64 M |
$20.16 M |
$9.82 M |
$25.22 M |
$14.51 M |
$343,884.00 |
| Interest Income |
$0.00 |
$26,667.00 |
$186,208.00 |
$1.09 M |
$181,413.00 |
$12,235.00 |
$663,017.00 |
| Interest Expense |
$44.83 |
$26,667.00 |
$186,208.00 |
$1.09 M |
$185,140.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$105,675.00
|
$109,004.00
|
$116,297.00
|
$125,333.00
|
$72,244.00
|
$23,077.00
|
$52,516.00
|
| EBITDA |
-$22.13 M
|
-$17.79 M
|
-$20.05 M
|
-$5.52 M
|
-$20.79 M
|
-$8.72 M
|
-$343,884.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$8.81 M
|
-$21.77 M
|
-$4.71 M
|
-$5.26 M
|
-$4.54 M
|
-$5.75 M
|
$663,017.00
|
| Income Before Tax |
-$22.28 M |
-$39.67 M |
-$20.35 M |
-$10.90 M |
-$25.40 M |
-$14.50 M |
$319,133.00 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$2.35 M |
$942,749.00 |
$23,204.00 |
$20,427.00 |
$9,496.00 |
-$1.00 |
$195,369.00 |
| Net Income |
-$19.94 M |
-$38.73 M |
-$20.32 M |
-$12.01 M |
-$25.39 M |
-$14.50 M |
$123,764.00 |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-52.6 |
-387.26 |
-247.86 |
-255.46 |
-875.66 |
-1449.54 |
12.38 |
| EPS Diluted |
-52.59 |
-387.18 |
-246.32 |
-251.32 |
-874.45 |
-1449.54 |
12.38 |
| Weighted Average Shares
Out |
$379,000.00
|
$100,000.00
|
$82,000.00
|
$47,000.00
|
$29,000.00
|
$10,000.00
|
$10,000.00
|
| Weighted Average Shares
Out Diluted |
$379,089.00
|
$100,021.00
|
$82,514.00
|
$47,774.00
|
$29,040.00
|
$10,000.00
|
$10,000.00
|
| Link |
|
|
|
|
|
|
|
